Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced that they have initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study (Assessment of KAN-101 in Celiac Disease), a Phase 1 clinical trial evaluating KAN-101 for the treatment of individuals with celiac disease. Initiation of the MAD cohort enrollment follows completion of the first two single-ascending dose (SAD) cohorts in the trial, with the third SAD cohort actively dosing patients. Read more about this important development, or see if you qualify to participate in the study.